» Articles » PMID: 22824479

A Myriad of Pathways to NASH

Overview
Journal Clin Liver Dis
Specialty Gastroenterology
Date 2012 Jul 25
PMID 22824479
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic steatohepatitis (NASH) is defined histopathologically by the presence of macrovesicular steatosis, cellular ballooning, and inflammation. NASH represents a complex multifactorial disease that typically occurs within the context of the metabolic syndrome. NASH lacks homogeneity, and other forms of NASH can present atypically. Less than 50% of patients with NASH respond to pharmacologic treatment, which speaks to this heterogeneity. The authors discuss drugs, disease entities, and nutritional states that can cause or exacerbate underlying NASH indirectly through worsening insulin resistance or directly by interfering with lipid metabolism, promoting oxidative injury, or activating inflammatory pathways.

Citing Articles

Metabolic Comorbidities and Risk of Development and Severity of Drug-Induced Liver Injury.

Li X, Gao P, Niu J Biomed Res Int. 2019; 2019:8764093.

PMID: 31531370 PMC: 6720367. DOI: 10.1155/2019/8764093.


Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent.

Dattaroy D, Seth R, Sarkar S, Kimono D, Albadrani M, Chandrashekaran V Eur J Pharmacol. 2018; 841:33-48.

PMID: 30194936 PMC: 7193950. DOI: 10.1016/j.ejphar.2018.08.040.


The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice.

Haczeyni F, Wang H, Barn V, Mridha A, Yeh M, Haigh W Hepatol Commun. 2018; 1(7):663-674.

PMID: 29404484 PMC: 5721439. DOI: 10.1002/hep4.1072.


Nonalcoholic fatty liver disease: Evolving paradigms.

Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi L World J Gastroenterol. 2017; 23(36):6571-6592.

PMID: 29085206 PMC: 5643282. DOI: 10.3748/wjg.v23.i36.6571.


Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.

Massart J, Begriche K, Moreau C, Fromenty B J Clin Transl Res. 2017; 3(Suppl 1):212-232.

PMID: 28691103 PMC: 5500243. DOI: 10.18053/jctres.03.2017S1.006.